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Abstract
Background: Although Traditional Chinese Medicine (TCM) has been widely used in clinical settings, a major
challenge that remains in TCM is to evaluate its efficacy scientifically. This randomized controlled trial aims to
evaluate the efficacy and safety of berberine in the treatment of patients with polycystic ovary syndrome. In order
to improve the transparency and research quality of this clinical trial, we prepared this statistical analysis plan (SAP).
Methods: The trial design, primary and secondary outcomes, and safety outcomes were declared to reduce
selection biases in data analysis and result reporting. We specified detailed methods for data management and
statistical analyses. Statistics in corresponding tables, listings, and graphs were outlined.
Discussion: The SAP provided more detailed information than trial protocol on data management and statistical
analysis methods. Any post hoc analyses could be identified via referring to this SAP, and the possible selection bias
and performance bias will be reduced in the trial.
Trial registration: This study is registered at ClinicalTrials.gov, NCT01138930, registered on 7 June 2010.
Keywords: Statistical analysis plan, Berberine, Polycystic ovary syndrome, Randomized controlled trial, Traditional
Chinese medicine
Update
This paper provides the detailed statistical analysis
plan (SAP) for “The effect of berberine on insulin
resistance randomized, placebo-controlled trial,”
comparing glucose disposal rate (GDR) at week 12.
Secondary endpoints and GDR at other time points
will provide exploratory results.
Background
Polycystic ovary syndrome (PCOS) is an ovarian disorder
characterized by hyperandrogenism, ovulatory dysfunc-
tion, and polycystic ovaries [1]. It is the most common
endocrinopathy affecting women of reproductive age,
and has attracted a lot of public attention for its relative
high prevalence both in communities and clinical
settings [2, 3]. Berberine is the major active component
of Rhizoma Coptidis, with a broad array of pharmaco-
logical effects [4]. Recently, several studies have shown
that berberine has positive effects on type 2 diabetes
mellitus, insulin resistance, lipid metabolism, nitric oxide
production, and the metabolic syndrome [5–8]. This study
is a multicenter, double-blind, randomized, placebo-
controlled clinical trial. The purpose is to compare the
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insulin resistance in PCOS patients with and without the
use of berberine. This study has been approved by
the Ethics Committee of the First Affiliated Hospital
Heilongjiang University of Chinese Medicine (2010HZYLL-
012) and informed consent was obtained from each patient
before any study procedures were performed. Full details of
the trial design of this randomized controlled trial (RCT)
are given in the study protocol which has been registered
and published [9]. Patients will be enrolled at four hospitals
in mainland China as stated in the protocol.
Despite Traditional Chinese medicine (TCM) having
been increasingly used in clinical settings, a major chal-
lenge in TCM is to evaluate its efficacy scientifically
[10]. The results of several studies have indicated the
low quality of RCTs in TCM [11, 12]. For example, a
recent study on bias of risk and outcome-reporting in
RCTs revealed inconsistencies between information from
trial registration and subsequent publications [13]. The
inconsistencies occurred mostly in statistical methods,
sample size, primary outcomes, safety reporting, and
outcome assessor blinding.
In the study protocol we detailed the overall design
and approaches. For a clinical trial, bias may also be
introduced in the post hoc selection of data manage-
ment procedures and the statistical analysis methods.
The SAP will provide more transparent information for
data analysis methods than the protocol. Besides, the
possible dispute and queries can be resolved by the
published SAP when publishing trial results. These
strategies and practices are important to improve the
scientific validity in the clinical research of Chinese
Medicine interventions. In order to improve the trans-
parency and research quality of our trial, we prepared
this SAP.
Inclusion criteria
1. Women aged between 18 and 35 years
2. Confirmed diagnosis of PCOS according to the
modified Rotterdam criteria, and all patients must
be anovulatory plus have either polycystic ovaries
and/or hyperandrogenism
3. Body Mass Index equal to or greater than 23 kg/m2
4. Women must not be pregnant and not expect to
become pregnant within 6 months
Exclusion criteria
1. Patients who are treated within the past 3 months
with other medications known to affect reproductive
function or metabolism, including oral
contraceptives, gonadotropin- releasing hormone
(GnRH) agonists and antagonists, antiandrogens,
gonadotropins, antiobesity drugs, Chinese herbal
medicines, antidiabetic drugs, such as metformin
and thiazolidinediones, somatostatin, diazoxide,
angiotensin-converting enzyme (ACE) inhibitors,
and calcium channel blockers
2. Patients with other endocrine disorders including
21-hydroxylase deficiency, hyperprolactinemia,
uncorrected thyroid disease, or suspected Cushing’s
syndrome
3. Patients with known severe organ dysfunction or
any mental illness
Sample size
It is assumed that women with PCOS would have an
insulin resistance comparable to women with type 2 dia-
betes. Based on a previous study [4], GDR was 7.42 ±
2.37 mg/(kg ×min) in the berberine group and 6.06 ±
2.21 mg/(kg ×min) in the control group. To detect this
difference between the two arms, the sample size
required was 52 per group, given a two-sided α = 0.05
(type I error) and β = 0.1 (type II error).
Randomization and allocation concealment
Eligible participants had been randomized into each of
the two arms: berberine (0.5 g, three times per day) or
placebo. Berberine or placebo medications were admin-
istrated orally for 12 weeks. Patients, investigators, and
physicians were blind to the assignment.
Data management
From the beginning of this study, a Data Management
Group has been formed (J Sun, YJ Zhang, K Zhang).
They were involved in setting up studies, collecting or
entering data, cleaning data, and managing accrual data
until the study could be considered ready for analysis.
The data in Case Report Form (CRF) all came from the
original files and the consistencies between the two
were monitored periodically. Data should be timely, ac-
curately, and integrally and veritably filled in the CRF.
The web-based data management system was also avail-
able at: http://www.medresman.org/login.aspx.
Guidelines for analysis
This SAP aims to detail the presentation and analysis
methods for the main paper(s) reporting results of this
study. Therefore, biases related to selective reporting
from our study could be reduced. International Council
on Harmonization (ICH) guidance on statistical princi-
ples for clinical trials (E9) [14] and the Consolidated
Standards of Reporting Trials (CONSORT) Statement
[15] for the reporting results were followed.
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Statistical analysis set
Intention-to-treat set
The intention-to-treat (ITT) set is defined as all patients
in the intervention (berberine or placebo) arms to which
they were randomized, regardless of the availability of
data at follow-up, and the real intervention that they
received during the period of the trial. Patients will be
included in the group to which they were randomized.
The ITT analysis will be reported mainly for efficacy
evaluation of primary and secondary outcomes. In addition,
ITT will be used in the balance testing of demographic
data, disease history, and laboratory examinations at
baseline.
Per-protocol set
The per-protocol set (PPS) includes patients who have
completed prescribed treatments in the whole trial
period without severe protocol violation.
The severe protocol violations will include (but not be
limited to) the following conditions:
1. Not meeting the inclusion criteria
2. The use of concomitant medication which may add
confounding to the estimation of efficacy and safety
3. Being beyond the time window, loss to follow-up, or
dropout
Any patients with varying degrees of protocol violation
will be confirmed in the blinded data review meeting.
Efficacy analyses will be carried out for both ITT and
PPS. If the results of the ITT and PPS are inconsistent,
sensitivity analyses will be conducted, and possible causes
will be investigated. Subgroup analyses by patients’ charac-
teristics, such as age, weight, Body Mass index, waist/hip
circumference ratio, etc. will be carried out.
Safety set
The safety set (SS) includes the patients who received at
least one-time medication treatment. The SS is the main
set of safety assessment in this trial.
Baseline demographic characteristics
Discrete variables will be summarized by frequencies and
percentages. Continuously distributed variables will be
summarized using either mean ± standard deviation (SD)
for data with normal distribution, or median and inter-
quartile range for nonnormally distributed data.
Primary outcome and hypothesis
The primary outcome is the change of GDR from baseline
to week 12. The GDR is defined as the amount of glucose
required to maintain stable blood glucose concentrations
during the last 30 min of the hyperinsulinemic-euglycemic
clamping. The mean value of change (μ), will be computed.
The relative efficacy of berberine on increasing GDR com-
pared to placebo will be tested at the one-sided significance
level of 0.025 under the null hypothesis and alternative hy-
pothesis as below:
H0: μBerberine = μPlacebo,
H1: μBerberine > μPlacebo.
Statistics relevant to the primary outcome, including
eligible number, mean, SD, median, interquartile range,
and minimum and maximum, will be calculated. A
paired Student’s t test/signed rank test will be used to
compare the difference between baseline and post
treatment within each group. The Analysis of Covari-
ance (ANCOVA) model will be constructed in estimat-
ing the difference of GDR between baseline and post
treatment. Covariates will be the baseline value of
GDR considering the effects of different sites and
groups. Based on this model, we will calculate least
squares means (LSMEANS) of the difference accom-
panying 95 % confidence interval between the two
groups. To explore the consistency of results across
centers, the interaction between treatment effect and
centers or groups will be added into the model. The
interaction effect will be considered statistically signifi-
cant when the P value for the interaction test is equal
to or less than 0.10. If the interaction is statistically
significant, further descriptive investigation will be
conducted in subgroups by sites.
Secondary outcomes and statistical methods
The secondary outcomes will be analyzed based on both
ITT and PPS:
1. Oral glucose tolerance test (OGTT): serum for
glucose, insulin, and c-peptide levels will be
determined.
The outcomes of the OGTT will be analyzed by the
t test/Wilcoxon rank sum test. The trapezoidal
method will be applied to calculate the area under
the curve (AUC) of OGTT values at different time
points [16] using the following formula:
X0min þ X180minð Þ=2 þ X30min þ X60min þ X120min:
2. Ovarian androgen biosynthesis as measured by
human chorionic gonadotropin (hCG), stimulated
production of 17-hydroxyprogesterone (17-OHP),
androstedione (A2), and testosterone (T) levels
3. Hormonal profile including: testosterone, sex
hormone-binding globulin (SHBG), follicle-stimulating
hormone (FSH), luteinizing hormone (LH), and dehy-
droepiandrosterone sulfate (DHEAS) levels
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4. Fasting lipid metabolic profile: cholesterol, triglycerides
(TG), high-density lipoprotein cholesterol (HDL-C),
and low-density lipoprotein cholesterol (LDL-C) levels
5. Weight, waist/hip circumference ratio, blood
pressure, Ferriman-Gallwey Score, and severity of
acne before and after treatment
Student’s t test or the Wilcoxon rank sum test will be
used to test the difference of the above outcomes be-
tween groups according to the distribution of variables.
Safety outcomes and statistical methods
Safety outcomes, including vital signs, adverse events,
and renal and liver function (including three categories:
normal, abnormal without clinical significance, and ab-
normal with clinical significance), will be analyzed based
on the SS.
Shift tables will be constructed to map the changes of
abnormal renal and liver function test results in each
visit. The vital signs comparison between groups at base-
line and post treatment and the changes relative to base-
line will be described with mean, SD or median and
interquartile range and Student’s t test or the Wilcoxon
rank sum test will be used accordingly. Adverse events
will be listed separately by type (nonserious adverse
events, serious adverse events), by visit, and by real
intervention.
Handling of missing data
The imputation will be carried out for primary and
secondary outcomes only. When analyzing the efficacy
in ITT, the Last Observation Carried Forward (LOCF)
imputation method will be used.
Interim analysis
No interim analysis was planned. All results and conclu-
sions will be derived from the final analysis of this trial.
CONSORT flow diagram
The profile of patients will be summarized in a CONSORT
flow diagram.
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